PPT-Raising the Bar in the Management of Advanced/Metastatic NSCLC

Dr Tan Jiunn Liang Clinical Specialist Respiratory Medicine Department of Medicine Universiti Malaya Medical Centre Disclaimer This program is provided as a service to the medical profession and represents the opinions of the speakers not necessarily those of Merck or MSD or its affiliates. Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW. (SUPPLEMENTARY SLIDES). Steven J. Kussick, MD, PhD Associate Medical Director. PhenoPath Laboratories. May 2016. Other Hematolymphoid Disorders, . Interview with Shirish M . Gadgeel. , MD . January 14, 2020. Case 1: 72-year-old woman enrolled on KEYNOTE-021. 2014: 72-year-old female patient with chest pain, cough and dyspnea is diagnosed with Stage IV squamous cell carcinoma. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. m. CSPC). 1. Neal Shore, MD, FACS. Carolina Urologic Research Center. Myrtle Beach, SC. Alicia Morgans, MD, MPH. Northwestern University. Chicago, IL. PROSTATE CANCER IS HORMONE DEPENDENT. 2. Huggins CB. Nobel lecture. Available from . . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory.